November 10, 2024 Wall Street Soars: Trump’s Victory Ignites Market Surge
November 2, 2024 Tech Titans’ Mixed Results Stall Wall Street Bull Run
October 28, 2024 Recent Oil Slides In Global Markets, Japan In Flux
Tesla’s Valuation: Unsupported By Fundamentals Or Future Growth
Tesla Stock Doesn’t Deserve This Rally
Nvidia: Q3 Earnings Could Ignite $200 Rally
Tesla: When Fundamentals Don’t Matter (Rating Downgrade)
Amazon Q3: Stop Buying The Stock For Now Because It’s Overvalued
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Absci (ABSI) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: November 14, 2024 (10:22)
Sector: HealthcareThe share price of Absci Corporation (ABSI) now
Analysts predictions
Full report
This Week
|
Neutral | Opinions: Na |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: 1 |
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Absci Corporation stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Absci stock price in 2024, 2025, 2026. How much will one Absci share be worth in 2024 - 2026?
When should I take profit in Absci stock? When should I record a loss on Absci stock? What are analysts' forecasts for Absci stock? What is the future of Absci stock? We forecast Absci stock performance using neural networks based on historical data on Absci stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Absci stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Absci shares. This happens once a day.
Historical and forecast chart of Absci stock
The chart below shows the historical price of Absci stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Absci stock price can be found in the table below.
Long-term forecasts by years.
Absci Corporation Analysts predictions review
As of now, Panda has combed through 1 analytical articles which are directly related to ABSI from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 1 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Oct 29, 2024 to Oct 29, 2024.
Absci's Pipeline: Balancing Innovative Promise with Financial Pressures
In the analytical financial article under review, seasoned analyst Richard Durant offers insights into ABSI stock, maintaining a Neutral stance on its potential trajectory. With an impressive tally of 615 publications since joining the platform in 2019, Durant's prolific output underscores his active engagement and expertise in financial analysis. Furthermore, his substantial subscriber base of 7,978 and excellent credibility position, reflective of a high authority rating, signify a deep trust in his balanced and informed viewpoints. His analyses, shaped by years of dedicated study and contribution, provide a reliable perspective for investors navigating ABSI stock, ensuring that readers receive well-considered advice grounded in substantial analytical experience.
Key Theses of the Analysis on Absci
- Absci's differentiated drug discovery platform has potential to create significant shareholder value long term.
- The company faces a long and expensive path to prove the effectiveness of its approach.
- While current cash burn is limited, anticipated increased costs might pressure share price in the future.
- Absci appears expensive relative to peers due to maintaining market favor despite broader industry pessimism.
Key Factors Influencing ABSI Stock Price
Positive Preclinical Data from ABS-101 program
The positive data announcement contributes to maintaining investor confidence and could lead to higher share prices, despite industry volatility. This strengthens investor interest and reduces the impact of broader industry setbacks.
Collaboration with Nvidia
The association with a leading AI company enhances Absci's credibility and investor appeal, providing a significant reputational boost. This collaboration is perceived as a strategic asset, positively influencing the stock price.
Limited Cash Burn
Current moderate cash burn reassures investors about financial stability in the near term amidst economic uncertainties. However, expected increased expenditures might reduce this comfort level in future evaluations, impacting stock perception.
Comparison to Peers
Absci's premium valuation compared to peers might attract initial investor skepticism, impacting stock sentiment. While it highlights investor confidence, further justifying this valuation could become a pressure point in the near future.
Partnerships and Collaborations
Partnerships with prestigious institutions like Memorial Sloan Kettering Cancer Center bolster Absci's project validation and resource sharing, positively impacting stock value. These partnerships enhance pipeline advancement while controlling costs, providing investor confidence in project fruition.
Cash Position and Future Capital Requirements
Absci's moderate cash position with anticipated future capital requirements could significantly impact share valuations, reflecting investor concerns over potential dilution and financial trajectory. The strategic timing of capital raises will be critical to stock performance in this context.
Review the original AnalysisAbsci's AI-Driven ABS-101: Poised for a Breakthrough in IBD Market
In reviewing the analytical financial article by Terry Chrisomalis, it's clear that the author maintains a Strong Bullish stance on ABSI stock. Chrisomalis, a seasoned contributor since 2013, has amassed an impressive 1,311 publications, underscoring his prolific nature and dedication to the field. With 12,819 subscribers, he possesses significant popularity, reflecting the collective interest and trust investors place in his insights. Given the high credibility of his viewpoints, as indicated by his impressive publishing track record and extensive tenure, Chrisomalis's analysis and insights carry considerable weight. Readers can confidently rely on his assessment of ABSI stock, taking into account his high authority and consistent engagement with financial analysis and market trends over the past decade.
Key Theses of the Review
- Absci Corporation's ABS-101 targets IBD using a novel AI-driven approach.
- The drug aims for unique advantages like de novo antibody creation and dosing flexibility.
- Global markets for Crohn's Disease and Ulcerative Colitis present significant opportunities.
- Interim data from the Phase 1 study of ABS-101 is expected in the second half of 2025.
Factors Influencing ABSI Stock Price
Initiation and Interim Data from Phase 1 Study
The successful launch and interim results of the Phase 1 study of ABS-101 could significantly boost investor confidence, leading to a positive impact on stock prices. Considering the innovative AI-driven approach, any early success will position Absci as a leader in the field, motivating stock appreciation.
Market Potential for Crohn's Disease and Ulcerative Colitis
The potential to tap into the combined markets valued at over $32 billion by 2033 underscores a massive revenue opportunity. Positive developments in ABS-101 could capture substantial market share, potentially increasing future earnings and stock valuation.
Financial Position and Funding Requirements
Absci has a decent cash position with $145.2 million as of June 2024, but it anticipates needing further fundraising within 12 months. Future stock dilution depends on share offerings which could temporarily pressure stock prices.
Competitive Environment
With competitors like Merck, Roche, and Sanofi also developing TL1A drugs, obtaining a competitive edge through innovation is vital. Any failure to differentiate its product effectively may hinder market penetration and affect stock performance.
Review the original AnalysisCommentary
Absci Corporation's innovative approach through ABS-101 is shaking up the biopharmaceutical landscape with its AI-driven drug development targeting IBD. On average, the blend of key factors such as the impending interim data release from the Phase 1 study and the massive market potential adds up to make a notable impact on ABSI’s stock trend. The company's technological edge and the anticipation of entering a lucrative $32 billion market for Crohn's Disease and Ulcerative Colitis bolster investor enthusiasm and suggest strong growth potential.
Overall, while Absci faces certain competitive challenges and fundraising needs, its current financial health and pioneering efforts imply a positive trajectory in the immediate future. The average influence of these factors in the next 15 days should suggest a reinforcement of the stock's bullish trend. Looking further out over the coming month, while stock dilution remains a risk, the anticipation surrounding ABS-101’s early results should continue propelling the stock upwards. This makes Absci's stock one to watch closely, especially as it positions itself as a leader in novel TL1A drug development.
Absci Corporation, an artificial intelligence-powered synthetic biology company, offers candidate biologics and production cell lines using an integrated drug discovery platform for partners in the United States. Its integrated drug discovery platform enables biologics to be created by integrating drug discovery and cell line development into a single process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Nov 16 | 3.35 | 3.24 | 3.46 | 6.95 |
Nov 17 | 3.29 | 3.23 | 3.40 | 5.08 |
Nov 18 | 3.32 | 3.23 | 3.41 | 5.62 |
Nov 19 | 3.34 | 3.21 | 3.42 | 6.56 |
Nov 20 | 3.52 | 3.42 | 3.66 | 6.99 |
Nov 21 | 3.42 | 3.25 | 3.55 | 9.14 |
Nov 22 | 3.51 | 3.41 | 3.61 | 5.99 |
Nov 23 | 3.58 | 3.51 | 3.63 | 3.49 |
Nov 24 | 3.57 | 3.49 | 3.62 | 3.61 |
Nov 25 | 3.53 | 3.44 | 3.60 | 4.56 |
Nov 26 | 3.42 | 3.37 | 3.53 | 4.68 |
Nov 27 | 3.51 | 3.43 | 3.67 | 7.06 |
Nov 28 | 3.50 | 3.44 | 3.62 | 5.00 |
Nov 29 | 3.43 | 3.38 | 3.60 | 6.46 |
Nov 30 | 3.56 | 3.46 | 3.63 | 4.81 |
Dec 01 | 3.51 | 3.35 | 3.68 | 9.67 |
Dec 02 | 3.66 | 3.58 | 3.81 | 6.51 |
Dec 03 | 3.79 | 3.61 | 3.91 | 8.06 |
Dec 04 | 3.68 | 3.62 | 3.76 | 3.78 |
Dec 05 | 3.70 | 3.60 | 3.85 | 6.77 |
Dec 06 | 3.72 | 3.63 | 3.85 | 6.15 |
Dec 07 | 3.56 | 3.47 | 3.69 | 6.27 |
Dec 08 | 3.72 | 3.55 | 3.77 | 6.22 |
Dec 09 | 3.92 | 3.78 | 4.01 | 6.16 |
Dec 10 | 3.90 | 3.72 | 4.07 | 9.57 |
Dec 11 | 4.02 | 3.85 | 4.18 | 8.46 |
Dec 12 | 4.14 | 4.07 | 4.28 | 5.19 |
Dec 13 | 4.15 | 4.08 | 4.24 | 3.85 |
Dec 14 | 3.98 | 3.88 | 4.15 | 7.09 |
Dec 15 | 3.85 | 3.73 | 3.95 | 5.94 |
Absci Daily Price Targets
Absci Stock Forecast 11-16-2024.
Forecast target price for 11-16-2024: $3.35.
Positive dynamics for Absci shares will prevail with possible volatility of 6.494%.
Pessimistic target level: 3.24
Optimistic target level: 3.46
Absci Stock Forecast 11-17-2024.
Forecast target price for 11-17-2024: $3.29.
Negative dynamics for Absci shares will prevail with possible volatility of 4.832%.
Pessimistic target level: 3.23
Optimistic target level: 3.40
Absci Stock Forecast 11-18-2024.
Forecast target price for 11-18-2024: $3.32.
Positive dynamics for Absci shares will prevail with possible volatility of 5.320%.
Pessimistic target level: 3.23
Optimistic target level: 3.41
Absci Stock Forecast 11-19-2024.
Forecast target price for 11-19-2024: $3.34.
Positive dynamics for Absci shares will prevail with possible volatility of 6.160%.
Pessimistic target level: 3.21
Optimistic target level: 3.42
Absci Stock Forecast 11-20-2024.
Forecast target price for 11-20-2024: $3.52.
Positive dynamics for Absci shares will prevail with possible volatility of 6.529%.
Pessimistic target level: 3.42
Optimistic target level: 3.66
Absci Stock Forecast 11-21-2024.
Forecast target price for 11-21-2024: $3.42.
Negative dynamics for Absci shares will prevail with possible volatility of 8.373%.
Pessimistic target level: 3.25
Optimistic target level: 3.55
ABSI (ABSI) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Dec. | 3.04 | 2.72 | 3.19 | 14.79 |
Absci forecast for this year
Absci Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $3.04109. Pessimistic: $2.72. Optimistic: $3.19
Absci (ABSI) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 3.65 | 3.42 | 3.82 | 10.44 |
Feb | 3.45 | 2.90 | 3.98 | 27.26 |
Mar | 2.86 | 2.56 | 3.32 | 23.14 |
Apr | 2.30 | 1.95 | 2.48 | 21.43 |
May | 2.52 | 2.35 | 2.88 | 18.23 |
Jun | 2.66 | 2.34 | 2.87 | 18.32 |
Jul | 2.78 | 2.51 | 3.15 | 20.40 |
Aug | 2.73 | 2.33 | 2.89 | 19.48 |
Sep | 3.12 | 2.64 | 3.62 | 26.98 |
Oct | 2.97 | 2.85 | 3.25 | 12.30 |
Nov | 2.81 | 2.36 | 2.96 | 20.35 |
Dec | 2.66 | 2.37 | 3.00 | 20.74 |
Absci (ABSI) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 2.43 | 2.09 | 2.63 | 20.38 |
Feb | 2.26 | 1.91 | 2.55 | 24.94 |
Mar | 2.54 | 2.41 | 2.84 | 15.19 |
Apr | 2.58 | 2.45 | 2.74 | 10.51 |
May | 2.71 | 2.54 | 3.09 | 17.67 |
Jun | 2.68 | 2.52 | 2.95 | 14.69 |
Jul | 2.89 | 2.68 | 3.15 | 14.83 |
Aug | 2.86 | 2.61 | 3.12 | 16.21 |
Sep | 2.92 | 2.48 | 3.27 | 24.15 |
Oct | 2.90 | 2.57 | 3.15 | 18.37 |
Nov | 3.47 | 3.10 | 4.03 | 23.14 |
Dec | 3.47 | 2.96 | 4.00 | 25.90 |
Absci information and performance
18105 SE MILL PLAIN BLVD, VANCOUVER, WA, US
Market capitalization of the Absci Corporation is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ABSI shares in the company outstanding by the market price of one share.
EBITDA of Absci is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.
Commentary
Absci's innovative drug discovery platform is poised to capture attention, bolstered by positive preclinical data and strategic partnerships, including a notable collaboration with Nvidia. These developments are instrumental, reflecting an average influence strength that leans positively in the short term and neutral in the coming month. The immediate 15-day outlook suggests resilience against broader industry trends due to these impactful collaborations, keeping investor confidence buoyed despite prevailing market volatility.
However, this optimism is tempered by the looming challenges of future capital requirements. Absci's current cash position provides temporary respite but anticipated expenses signal forthcoming pressures. Investors must weigh the company's premium valuation against these financial demands, with partnerships aiding in offsetting costs. As such, the valuation sentiment remains mixed, bordered between enthusiasm over strategic moves and caution over fiscal sustainability. The next month could see Absci treading on neutral grounds as it maneuvers through its fiscal realities, setting the stage for carefully strategized capital raises.